Based on the recently published consensus statement by Petersenn et al., dopamine agonists, particularly cabergoline, are highly effective in lowering serum prolactin levels, reducing tumor size, and improving the clinical manifestation of patients with prolactin-secreting pituitary adenomas. The gene discussed is PRL; the disease is pituitary gland adenoma.